#1 Clinical Trials Search in Europe

Sulfamethizole

This article discusses the use of Sulfamethizole, an antibiotic medication, in clinical trials for treating Gram-negative bacteremia. The focus is on a study comparing short-course (5 days) and standard (7+ days) antibiotic treatments for patients with urinary tract infections leading to bloodstream infections. The trial aims to assess the efficacy and safety of shortened antibiotic duration in hospitalized immunocompetent adults.

Table of Contents

What is Sulfamethizole?

Sulfamethizole is an antibiotic medication that belongs to a class of drugs called sulfonamides. It is used to treat various bacterial infections, particularly those affecting the urinary tract. The medication is also known by its brand name “Sulfametizol ‘Alternova'” and is available in tablet form.[1]

Medical Conditions Treated

Sulfamethizole is primarily used to treat infections caused by certain types of bacteria. Based on the clinical trial information provided, it is being studied for its effectiveness in treating:

  • Gram-negative bacteremia: This is a serious condition where harmful bacteria are present in the bloodstream.[1]
  • Urinary tract infections: These are infections that can affect any part of the urinary system, including the kidneys, bladder, and urethra.[1]

How Sulfamethizole is Used

Sulfamethizole is typically taken orally in tablet form. The dosage and duration of treatment may vary depending on the specific condition being treated and the patient’s individual needs. According to the clinical trial information:

  • The maximum daily dose is 2000 mg (milligrams).[1]
  • The maximum total dose for a treatment course is 14000 mg.[1]
  • The maximum treatment period being studied is 7 days.[1]

It’s important to note that these dosages are specific to the clinical trial and may not reflect the typical use of Sulfamethizole in general practice. Always follow your healthcare provider’s instructions when taking any medication.

Clinical Trial Information

A clinical trial is currently being conducted to study the effectiveness of Sulfamethizole in treating Gram-negative bacteremia with a urinary tract source of infection. The study is titled “Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study”.[1]

The main objective of this study is to assess whether a shorter antibiotic treatment duration (5 days) is as effective and safe as the standard longer treatment (7 days or more) for Gram-negative bacteremia in hospitalized adults with a urinary tract infection source.[1]

Eligibility Criteria for the Study

To participate in this clinical trial, patients must meet certain criteria. Some key inclusion criteria are:

  • Blood culture positive for Gram-negative bacteria[1]
  • Evidence of urinary tract infection[1]
  • Antibiotic treatment started within 12 hours of first blood culture[1]
  • Normal body temperature and clinically stable condition at the time of randomization[1]

There are also several exclusion criteria, such as recent antibiotic treatment, immunosuppression, and pregnancy or breastfeeding.[1]

Study Objectives and Endpoints

The primary goal of the study is to evaluate the 90-day survival rate without clinical or microbiological treatment failure.[1] Other important aspects being studied include:

  • Mortality rates at different time points[1]
  • Total duration and type of antibiotic treatment[1]
  • Length of hospital stay and readmission rates[1]
  • Antibiotic-related adverse events[1]
  • Development of antibiotic resistance[1]

Potential Side Effects and Monitoring

While the study is ongoing and specific side effects for Sulfamethizole are not detailed in the provided information, the clinical trial is monitoring for several potential issues, including:

  • Antibiotic adverse events: These are unwanted effects that may occur as a result of antibiotic use.[1]
  • Severe adverse events: These are serious health issues that may or may not be related to the medication.[1]
  • Acute kidney injury: This is a sudden decrease in kidney function.[1]
  • Clostridioides difficile infection: This is a type of bacterial infection that can occur as a result of antibiotic use.[1]
  • Development of multidrug-resistant organisms: These are bacteria that have become resistant to multiple types of antibiotics.[1]

It’s important to note that all medications can have side effects, and the benefits and risks should be carefully considered by healthcare providers when prescribing any treatment.

Aspect Details
Study Type Multicenter, randomized, non-blinded, non-inferiority interventional study
Condition Gram-negative bacteremia with urinary tract source
Intervention 5 days of antibiotic treatment vs. 7+ days of antibiotic treatment
Primary Outcome 90-day survival without clinical or microbiological failure
Key Inclusion Criteria Positive blood culture for Gram-negative bacteria, evidence of urinary tract infection, clinically stable
Key Exclusion Criteria Immunosuppression, recent antibiotic treatment, pregnancy or breastfeeding
Drug Information Sulfamethizole (Sulfametizol “Alternova”), tablet form, maximum daily dose 2000 mg, maximum total dose 14000 mg
Secondary Outcomes Mortality, antibiotic duration, hospital stay length, adverse events, antibiotic use after discharge

FAQ

  • What is Gram-negative bacteremia? Gram-negative bacteremia is a serious blood infection caused by Gram-negative bacteria, often originating from a urinary tract infection. It can lead to severe complications if not treated properly.
  • What is the main goal of the clinical trial using Sulfamethizole? The main goal is to assess the effectiveness and safety of a shorter antibiotic treatment duration (5 days) compared to the standard treatment (7 days or more) for Gram-negative bacteremia with a urinary tract source in hospitalized adults with normal immune systems.
  • Who can participate in this clinical trial? Participants must have a positive blood culture for Gram-negative bacteria, evidence of a urinary tract infection, be clinically stable, and have received antibiotic treatment within 12 hours of the first blood culture. They must also provide informed consent.
  • What are some reasons why someone might not be eligible for this trial? Exclusion criteria include recent antibiotic treatment, recent Gram-negative bacteremia, immunosuppression, pregnancy or breastfeeding, and infections with certain types of bacteria like Pseudomonas or Acinetobacter.
  • What is the primary outcome being measured in this trial? The primary outcome is 90-day survival without clinical or microbiological failure to treatment. This means researchers will check if patients survive and recover from the infection within 90 days after starting the treatment.

Ongoing Clinical Trials on Sulfamethizole

  • Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

Glossary

  • Gram-negative bacteremia: A serious blood infection caused by Gram-negative bacteria, which are a type of bacteria that do not retain a certain dye in a laboratory test. These infections often originate from the urinary tract.
  • Sulfamethizole: An antibiotic medication used to treat various bacterial infections, including urinary tract infections. It belongs to a class of drugs called sulfonamides.
  • Non-inferiority study: A type of clinical trial that aims to show that a new treatment is not worse than a standard treatment by more than a pre-specified amount.
  • Immunocompetent: Having a normally functioning immune system that can fight off infections and diseases effectively.
  • Polymicrobial: Involving or caused by more than one type of microorganism, such as multiple types of bacteria.
  • Clostridioides difficile infection: A type of bacterial infection that can cause diarrhea and other intestinal problems, often occurring after antibiotic use.
  • Multidrug-resistant organism: A type of bacteria that has developed resistance to multiple types of antibiotics, making infections harder to treat.
  • Acute kidney injury: A sudden decrease in kidney function, which can be a potential side effect of some medications or severe infections.

References

  1. http://clinicaltrials.eu/trial/study-on-shortened-antibiotic-treatment-for-gram-negative-bacteremia-in-hospitalized-adults-using-pivmecillinam-hydrochloride-and-drug-combination/